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Chimerism was demonstrated with immunocytochem-
ical and/or polymerase chain reaction techniques in kid-
ney allografts and in the native skin, lymph nodes, or 
blood of 5 of 5 patients who received continuously func-
tioning renal transplants from 1 or 2 haplotype HLA 
mismatched consanguineous donors (4 parents, 1 aunt) 
27-29 years ago. In the 4 cases where the kidney donor 
still was alive to provide stimulator lymphocytes for 
testing, these provoked no (n=2) or modest (n=2) MLR 
in contrast to vigorous MLR to third party lymphocytes. 
In all 4 cases, the donor cells failed to generate in vitro 
cytotoxic effector cells (cell-mediated lymphocytotoxic-
ity). These findings are in accord with the hypothesis 
that cell migration, repopulation, and chimerism are 
seminal events that define graft acceptance and ulti-
mately can lead to acquired donor-specific nonrespon-
siveness (tolerance). 
We postulated recently that the acceptance of whole organ 
transplants connotes a state of long-term mixed allogeneic or 
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partment of Surgery, 3601 Fifth Avenue, 5C Falk Clinic, Univeristy of 
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xenogeneic chimerism after the migration from the graft and 
widespread seeding in the recipient of dendritic and other 
immune cells; simultaneous chimerism of the graft is produced 
by a reverse traffic of similar recipient cells (J). Our hypothesis 
further holds that the bidirectional cell migration and repopu-
lation is the first step in the acquisition of donor-specific 
immunologic nonresponsiveness (tolerance). The changes in 
the graft and in recipient tissues has been easiest to prove after 
liver (2, 3) or intestinal (4, 5) transplantation because of the 
dense population of potentially migratory cells in these organs. 
However, we report here the same kind of chimerism on a 
smaller scale in 5 patients who have born kidney allografts for 
27-29 years. 
MATERIALS AND METHODS 
Case Material 
The 5 kidney recipients who now are 45.20±1.79 (SD) years old 
(range 43-47) underwent renal transplantation at the University of 
Colorado between July 1963 and July 1965 under AZA-PRED immu-
nosuppression (6) (Table 1). They were selected for the present study 
in preference to our other survivors from this early era because: (a) 4 
of the 5 donors still are alive, allowing their HLA retyping and use of 
their lymphocytes for studies of immunologic reactivity of the recipient; 
(b) known HLA incompatibilities between the foregoing 4 donors and 
their recipients permitted immunocytochemical and polymerase chain 
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TABLE 1. Clinical data 
LD numbers 
17 33 51 52 90 
Transplantation 7 -19-63 10-7-63 2-10-64 2-17-64 7-23-65 
Recipient sex F F M F F 
Donor relation Mother Mother Aunt Father Mother 
PRED (mg/day) 2.5 0 10 7.5" 7.5" 
AZA (mg/day) 75 100 125 50 
Creatinine mg% 0.7 1.2 1.6 0.9 1.8 
BUN mg% 6 15 19 13 21 
a Dose of 15 mg every other day. 
reaction (PCR") distinction of donor from recipient cells in the biopsy 
tissues from the recipients; (c) in the fifth case (LD 52), in which the 
donor (father to daughter) had died, chimerism in tissues could be 
determined by sex typing. 
The 5 recipients underwent bilateral nephrectomy and splenectomy 
at the time of transplantation. Their current medications and renal 
functions are shown in Table 1. Patient 52 has received no AZA for 12 
years. The current steroid doses have been fixed> 25 years. 
Determination of Chimerism 
Each tissue biopsy specimen was obtained with separate sterile 
instruments to ensure against genetic contamination. The biopsy of 
the kidney allograft was performed in one room and the patient was 
then moved to a different operating room, where the skin and lymph 
node biopsies were obtained from a freshly sterilized field in the groin. 
Portions of the biopsies were fixed in 10% formalin for conventional 
staining, or else immediately frozen in optimal cold temperature com-
pound or liquid nitrogen for immunocytochemistry or DNA typing, 
respectively. 
Immunocytochemistry (ICC). Both donors and recipients were freshly 
typed (Table 2). From the class I and class II HLA Ags present in the 
donor but not the recipient, mABs were chosen from a library and used 
for phenotyping of the kidney, skin, and lymph node biopsies (Table 
3). Both indirect immunofluorescence and immunoperoxidase (avidin-
biotin-complex) methods were used. Antibodies of the same Ig class 
that were reactive with the recipient but not the donor provided positive 
controls, and Ig class-matched anti-MHC antibodies that reacted with 
neither were negative controls. A tissue was considered chimeric when 
cells stained with both recipient-specific and donor-specific HLA an-
tibodies, but not with nonspecific MHC antibodies. 
The tissues from the female patient who received her father's kidney 
were examined after in situ hybridization using a cocktail of cloned, 
biotinylated DNA probes directed against satellite DNA sequences 
specific for the Y chromosome (Oncor Inc., Gaithersburg, MD). For-
malin-fixed, paraffin-embedded tissues were deparaffinized, partially 
digested, and hybridized overnight. High stringency washes were fol-
lowed by an amplified avidin-fluorescein detection system (Oncor). 
Tissues of known sex served as controls. In addition, the male allograft 
organ served as a fixation and digestion control within each run. Tissues 
were examined and photographed using a Nikon Optiphot II epifluo-
rescence microscope. 
PCR. HLA-DRB molecular typing was performed according to the 
reference protocol of the XI International Histocompatibility Work-
shop in which preliminary generic amplification of the DRB gene is 
performed to decide which allele-specific amplifications must be done 
and which allele-specific oligonucleotide probes must be tested in the 
dot-blot hybridization analyses (7). 
In the case where the paternal donor to a daughter recipient had 
died (LD 52), oligonucleotides specific for the satellite region of the Y 
chromosome centromere (8) and for the sex-determining region of the 
Y chromosome (9) were used as primers to determine the presence of 
DNA from the donor in the patient tissues. After Southern blotting, 
* Abbreviations: CML, cell-mediated Iymphocytotoxicity; ICC, im-
munocytochemistry; PCR, polymerase chain reaction. 
the amplified material was hybridized to radioactively labeled Y-spe-
cific probes to confirm the specificity of the bands visualized in an 
agarose gel after ethidium bromide staining. 
Immunologic Studies 
MLR. Unidirectional human MLR cultures were set up for 6 days 
with 5x104 responder and 5X104 irradiated (2000R) stimulator cells in 
a volume of 200 ~l of tissue culture medium supplemented with 5% 
human serum. Proliferation was assessed by the degree of [3Hjthymi-
dine incorporation during the final 20 hr of incubation. 
Cell-Mediated Lymphocytotoxicity (CML). The cytolytic activity of 
recipient lymphocytes toward donor and third party targets was as-
sessed in cell-mediated lympholysis assays. In these assays, effector 
lymphocytes were incubated with Cr-Iabeled target cells at various E:T 
ratios, ranging from 10:1 to 30:1. 
RESULTS 
Evidence of Chimerism 
ICC. The donor HLA specificity of the renal allografts after 
27-29 years was most easily demonstrated in the vascular 
endothelial cells (Fig. lA). In contrast, the Y probe in case LD 
52 showed the male marker in the renal tubules (Fig. 2A). 
All 5 of the recipients had small numbers of donor cells in 
their lymph nodes (Fig. lB), skin (Fig. 2B), or both (Table 3). 
The smallest number of donor cells was in the female recipient 
of a paternal kidney. The number of donor cells in recipient 
tissues never exceeded 1 % and usually was estimated to be < 
0.1%. 
PCR. In the 4 cases in which blood was available from both 
the donor and recipient (LDI7, 33, 51, 90), genomic DNA was 
extracted from the peripheral blood lymphocytes of the recipi-
ent. In addition, the blood of the respective donors, together 
with the biopsies of lymph nodes and skin of the recipients, 
were used for DNA extraction. The amplification with HLA-
DRB "generic" primers was successful in all cases and allowed 
us to chose the primers for the allele-"specific" amplifications 
(Figs. 3 and 4). Tissue chimerism was demonstrated in all 4 
cases, and in 2 there also was blood chimerism (Table 4). 
In the woman whose paternal donor had died (LD 52), the 
detection of the Y chromosome in her skin showed the presence 
of donor (male) cells in the recipient (female) tissues. As in all 
the other cases, the allograft also was a chimeric structure. 
Immunologic Studies 
MLR. Lymphocytes from 2 of the 4 kidney recipients (33 and 
51) whose donors are still alive failed to respond in vitro to 
irradiated donor cells while showing a normal proliferative 
response to third party unrelated control cells (Table 5). Lym-
phocytes from kidney recipients 17 and 90 showed normal and 
modest responses, respectively, to their mothers' one haplotype 
mismatched donor cells and a good response to third party 
lymphocytes. 
When the MLR was done the other way around, using 
irradiated recipient cells to stimulate donor lymphocytes, the 
donor cells were totally nonreactive to the lymphocytes of 
recipient 51 or had reduced reactivity to the cells of recipients 
17, 33, and 90, but reacted vigorously to third party control 
cells (Table 5). Both recipient and donor cells stimulated un-
related third party lymphocytes (Table 5, footnote). 
CML. All 4 recipients generated significant cytotoxic activity 
(CML activity >15%) when cultured with third party control 
cells. However, these recipient lymphocytes failed to generate 
in vitro cytotoxic effector cells when stimulated by their donors 
(CML activity <10%), including recipient 90, whose cells had 
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TABLE 2. HLA phenotypes 
Recipient 
Case 
A B BW DR DQW 
17 3,26 35,- 6,- 1,15 1,-
33 2,3 7,27 4,6 1,13 1,-
51 24,29 44,55 4,6 4,7 3,-
52 Female 
90 1,28 35,57 4,6 4,15 1,3 
TABLE 3. lmmunostaining for donor-specific chimerism 
Number of 
positive cells/ 
Patien t Donor-specific 
Positive Staining section 
HLA·mAbs tested for donor HLA 
Lymph Skin' 
nodes' 
17 6 B44 <10 0 
33 1 B18 <10 < 10 
51 2 B7,40 10- 20 0 
A3 <10 <5 
52 Y probe N/ A 0 2 
90 5 DQW2 <10 <5 
a Scattered in paracortex and more cells in lymph node capsule. 
b Located in periarterial advential space and connective tissue. 
proliferated in the presence of donor cells (Table 5). This kind 
of CML nonresponsive ness has been documented during the 
first year after kidney transplantation under AZA and PRED 
(J 0), and was reported by Thomas et al. (I 1) to be a consistent 
finding in patients still bearing functional renal grafts up to 12 
years after transplantation by Dr. David Hume of Richmond, 
VA. 
DISCUSSION 
Biopsies in all 5 of the long-surviving renal allograft recipi-
ents showed low level chimerism. This was identified by im-
munostaining of discrete cells of donor type in host lymph 
nodes and skin, and by confirmation in all 5 cases of donor 
DNA in the tissues with PCR techniques. In addition, 2 of the 
patients were blood chimeras by PCR. The subtlety of the 
chimerism in the skin and lymph nodes versus much more overt 
fmdings in liver transplant recipients (2,3) apparently reflected 
the relative paucity of the migratory leukocytes in the kidney 
compared to the liver. This could explain why tolerance of the 
renal allograft is harder to induce (1). 
To increase the tolerogenicity of organs such as the kidney 
and heart that have a small migratory leukocyte constituency, 
the therapeutic possibility has been discussed elsewhere of 
augmenting cell migration to the level naturally enjoyed by the 
immunologically privileged liver (1). The most obvious expe-
dient is the concomitant infusion of bone marrow from the 
organ donor, as has been advocated by Monaco et al. (12-15) 
and Thomas et al. (16, 17) for tolerance induction of kidneys 
and carried out clinically by Barber et al. (18), Van Twuyver 
et al. (19) have speculated that the tolerogenic effects of blood 
transfusion for conditioning of patients for kidney transplant 
recipiency could be due under certain conditions to the homing 
in of transfused lymphocytes to privileged sites, resulting in 
mixed allogeneic chimerism, All 5 of our kidney recipients had 
undergone splenectomy, However, the presence or absence of a 
spleen was not an important factor in the chimeric state of a 
Donor 
A B BW DR DQW 
1,3 35,44 4,6 7,15 1,2 
2,- 18,27 4,6 1,4 1,3 
3,- 7,- 6,- 4,2 1,3 
Male (Father) 
I ,ll 57,62 4,6 4,7 2,3 
: , :~~ f a K " 
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FIGURE 1. Kidney allograft (A, 450x) and recipient lymph node (B, 
100X) stained with anti-HLA B 7,40 mAb using an avidin-biotin 
complex method, The rust-colored endothelial cells in the kidney and 
scattered cells in the lymph node are of donor origin, (C) (lOOx) The 
negative control in which anti-A2, 28 (irrelevant class-matched anti-
body) was used as the primary antibody, 
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FIGURE 2. Fluorescent in situ hybridization for the Y chromosome. 
(Al Kidney allograft showing the male (Y) marker in over 50% of the 
tubular epithelial cells. (B) Y marker (arrow) in a skin biopsy (both 
photomicrographs 1000X). 
DB RB RL RS C 
7011 • • 
7002 
8603 
-
• 
FIGURE 3. LD51: Chimerism demonstrated with PCR. After PCR 
amplification of HLA-DRB genes with "generic" oligo primers and 
hybridization of this material with allele-specific oligo probes, the 
recipient tissues were typed as DR4 (probe 1004) and DR7 (probe 
1006). The donor blood was positive for probes 1004 (DR4), shared 
with the recipient, and 7011 (DR2). The amplified DNAs from donor 
blood (DB), recipient lymph nodes (RL), and recipient skin (RS) 
obtained using DR2 "specific" oligo primers were successfully hybrid-
ized with the allele-specific oligo probes 7011 and 8603, which recognize 
the DR2 allele of the donor. Probes 7002, 7003, and 8601 were negative. 
C is the negative control. In this experiment, the blood of the recipient 
(RB) was not positive. 
series of long-surviving liver recipients, all of whom were chi-
meras (2, 3,20). 
The critical migratory cells may be the dendritic cells (21) 
that previously were known as passenger leukocytes (22, 23)_ 
DB RB RL RS c 
FIGURE 4. LD 90: PCR demonstration with Southern blot technique 
of chimerism in blood (RB), lymph node (RL), and skin (RSl of the 
recipient as detected with DR7 (donor) specific oligo probes after 
preliminary steps described in Figure 3. C is the negative control. DB 
is donor blood DNA diluted 100 times to avoid overwhelming the other 
bands. 
TABLE 4. PCR 
Donor-specific Donor-specific Tissue distribution Patient 
allele probe Blood L-node Skin 
17 DR7 0701 + 
33 DR4 0409 + + 
51 DR2 1501 + + 
52 Y chromosome SRY + 
90 DR7 0701 + + + 
TABLE 5. MLR of recipient and donor lymphoid cells 
Responder cells 
Stimulator cells d Recipient Recipient Recipient Recipient 
17 (cpm) 33 (cpm) 51 (cpm) 90 (cpm) 
Self 845 193 163 968 
Donor (kidney) 17,458 186 302 14,835 
Third party HLA- 19,357 87,338 9,563 98,481 
unrelated 
Donor for Donor for Donor for Donor for 
17 33 51 90 
Self 1,122 148 133 518 
Recipient 8,168 2,789 138 26,244 
Third party HLA- 15,041 57,Q62 5,760 122,347 
unrelated 
a Stimulator lymphocytes were irradiated 2000 R. 
b In controls of the stimulatory capacity of recipient and donor 
peripheral blood lymphocytes, the response of third party peripheral 
blood lymphocytes (net cpm) were as follows: case 17 (57,388 recipient/ 
44,468 donor), case 33 (9,733/17,936), case 51 (5,327/9,826), and case 
90 (67,432/ 63,377). cpm, counts/ minute thymidine incorporation. 
However, there are very few clues about how these cells of bone 
marrow orgin, whose life expectancy after maturation has been 
said to be days or weeks (24), have disseminated from the grafts 
and perpetuated themselves for nearly 30 years in their new 
environment. Inaba et al. (25) recently demonstrated stem cells 
in mouse blood that could be grown selectively in culture 
enriched with GM/CSF. However, it is unlikely that residual 
blood in allografts deliberately perfused to an asanguinous state 
could be a consistent source of stem cells that replicate in the 
recipients. The migratory cells, which generate progeny, could 
be hematopoetic stem cells that come in small numbers from 
the interstitium of the transplanted organ under conditions 
that are propitious in the perioperative period for migration, 
engraftment, and self-renewal. It was noteworthy that 2 of our 
5 patients had circulating donor DNA demonstrated by peR 
27 and 29 years post-transplantation. 
In the past, the clinical meaning of tolerance has been 
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construed as permanent engraftment in the absence of contin-
uing therapy. We have suggested that such drug-free classical 
tolerance and the "graft acceptance" achieved with chronic 
immunosuppression are both expressions of the cell repopula-
tion (1). The achievement of a potentially drug-free state 
probably is not rare after kidney transplantation, particularly 
if well-matched family donors are used. Of the first 64 patients 
in the original University of Colorado series (26), 10, including 
the first 4 in the present study, still bear their original consan-
guineous transplants, which are among the 16 longest contin-
uously functioning allografts in the world (27). Two of these 
10 recipients who had HLA-compatible donors have perfect 
renal function after stopping all medications more than 26 
years ago (28). In addition, Patient LD 52 of this report, who 
has a one haplotype mismatched graft, has been only on 7.5 
mg/day PRED for more than 12 years. 
The practical problem is how to determine when the need 
for treatment ends and the drug-free state begins. Strober et 
a1. (29) documented tolerance by discontinuance of treatment 
soon after transplantation in 3 cadaveric kidney recipients 
whose immunosuppression was with 20 Gy total lymphoid 
irradiation, a perioperative course of antithymocyte globulin, 
and maintenance PRED that was gradually weaned and even-
tually stopped. Donor-specific nonreactivity of lymphocytes 
from their drug-free patients was demonstrated with MLR and 
CML. In 4 of our 5 cases, the availability for blood sampling of 
the original kidney donors allowed these same in vitro immu-
nologic tests to be done. The results showed absolute donor-
specific nonresponsiveness with MLR in 2 cases, relative non-
responsiveness in the 2 others, and an inability in all 4 cases 
of the donor lymphocytes to stimulate a CML response. Unfor-
tunately, donor-specific nonresponsiveness with either MLR or 
CML (or both) does not provide complete assurance of stable 
graft acceptance without immunosuppression in experimental 
animals (30) or humans (l0, 11). Conversely, the demonstra-
tion of in vitro antigraft reactivity does not necessarily imply 
instability (31). This means that the late discontinuance of 
therapy still has an element of trial and error. 
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